Clovis Oncology Beheer
Beheer criteriumcontroles 3/4
De CEO Clovis Oncology is Patrick Mahaffy, benoemd in Apr2009, heeft een ambtstermijn van 14.25 jaar. bezit rechtstreeks 0.67% van de aandelen van het bedrijf, ter waarde $ 14.56K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.4 jaar en 14.3 jaar.
Belangrijke informatie
Patrick Mahaffy
Algemeen directeur
n/a
Totale compensatie
Percentage CEO-salaris | n/a |
Dienstverband CEO | 14.3yrs |
Eigendom CEO | 0.7% |
Management gemiddelde ambtstermijn | 7.4yrs |
Gemiddelde ambtstermijn bestuur | 14.3yrs |
Recente managementupdates
Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Sep 30 2022 | n/a | n/a | -US$252m |
Jun 30 2022 | n/a | n/a | -US$263m |
Mar 31 2022 | n/a | n/a | -US$258m |
Dec 31 2021 | US$3m | US$739k | -US$265m |
Sep 30 2021 | n/a | n/a | -US$299m |
Jun 30 2021 | n/a | n/a | -US$310m |
Mar 31 2021 | n/a | n/a | -US$336m |
Dec 31 2020 | US$3m | US$721k | -US$369m |
Sep 30 2020 | n/a | n/a | -US$370m |
Jun 30 2020 | n/a | n/a | -US$385m |
Mar 31 2020 | n/a | n/a | -US$413m |
Dec 31 2019 | US$7m | US$719k | -US$400m |
Sep 30 2019 | n/a | n/a | -US$400m |
Jun 30 2019 | n/a | n/a | -US$396m |
Mar 31 2019 | n/a | n/a | -US$377m |
Dec 31 2018 | US$6m | US$689k | -US$368m |
Sep 30 2018 | n/a | n/a | -US$321m |
Jun 30 2018 | n/a | n/a | -US$291m |
Mar 31 2018 | n/a | n/a | -US$366m |
Dec 31 2017 | US$9m | US$636k | -US$346m |
Sep 30 2017 | n/a | n/a | -US$365m |
Jun 30 2017 | n/a | n/a | -US$370m |
Mar 31 2017 | n/a | n/a | -US$324m |
Dec 31 2016 | US$789k | US$224k | -US$349m |
Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Patrick redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.
Compensatie versus inkomsten: De vergoeding van Patrick is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Patrick Mahaffy (60 yo)
14.3yrs
Tenure
US$2,639,083
Compensatie
Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 14.3yrs | US$2.64m | 0.67% $ 14.6k | |
Executive VP & CFO | 7.3yrs | US$1.19m | 0.072% $ 1.6k | |
Executive VP | 7.5yrs | US$1.20m | 0.068% $ 1.5k | |
Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer | 7.9yrs | US$1.24m | 0.078% $ 1.7k | |
Executive VP & Chief Scientific Officer | 3.8yrs | geen gegevens | geen gegevens | |
Executive Vice President of Human Resources | 6.8yrs | geen gegevens | geen gegevens |
7.4yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CLVS.Q is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.4 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 14.3yrs | US$2.64m | 0.67% $ 14.6k | |
Independent Director | 14.3yrs | US$260.00k | 0.041% $ 889.9 | |
Independent Director | 14.5yrs | US$270.00k | 0.040% $ 875.1 | |
Independent Director | 14.5yrs | US$270.00k | 0.17% $ 3.8k | |
Independent Director | 14.5yrs | US$270.00k | 0.044% $ 953.2 | |
Independent Chairman | 10.5yrs | US$287.50k | 0% $ 0 | |
Independent Director | 14.5yrs | US$257.50k | 0.040% $ 872.7 | |
Director | 2yrs | US$375.21k | geen gegevens | |
Independent Director | 10.5yrs | US$259.58k | 0% $ 0 | |
Independent Director | 4.8yrs | US$257.50k | 0% $ 0 | |
Independent Director | 4.8yrs | US$255.00k | 0% $ 0 |
14.3yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CLVS.Q zijn ervaren en ervaren (gemiddelde ambtstermijn van 14.3 jaar).